Table 1.
Baseline characteristics of IgAN patients with various crescents forming.
| Characteristics | 0% (N = 16) | 0%–24% (N = 24) | 25%–49% (N = 27) | 50%–74% (N = 21) | 75%–100% (N = 12) | Total (N = 100) | P-value |
|---|---|---|---|---|---|---|---|
| Male (%) | 9 (56.3%) | 17 (70.8%) | 17 (63.0%) | 17 (81.0%) | 8 (66.7%) | 68 (68.0%) | 0.550 |
| Age | 31.8 ± 7.8 | 40.1 ± 11.6 | 39.1 ± 14.0 | 32.5 ± 12.0 | 34.2 ± 15.4 | 36.2 ± 12.5 | 0.096 |
| SBP (mmHg) | 127.4 ± 15.3 | 133.6 ± 21.9 | 133.4 ± 24.2 | 147.0 ± 18.0 | 136.3 ± 15.2 | 135.7 ± 20.8 | 0.051 |
| DBP (mmHg) | 80.9 ± 11.5 | 86.0 ± 13.7 | 82.0 ± 16.5 | 90.8 ± 16.6 | 80.6 ± 10.8 | 84.5 ± 14.8 | 0.159 |
| Scr (µmol/L) | 89.0 (71.3–136.1) | 122.7 (88.1–166.6) | 182.1 (94.9–333.5) | 398 (289.9–511.6) | 292.5 (201.8–686.8) | 163.5 (97.3–375.9) | <0.001 |
| Proteinuria (g/day) | 0.9 (0.5–3.7) | 1.8 (1.1–3.3) | 2.4 (1.4–5.3) | 5.5 (4.2–7.4) | 5.4 (3.5–8.4) | 3.4 (1.4–5.6) | <0.001 |
| Albumin (g/L) | 39.9 ± 3.8 | 36.6 ± 5.1 | 34.2 ± 5.5 | 31.7 ± 5.1 | 28.1 ± 7.2 | 34.4 ± 6.3 | <0.001 |
| IgG (g/L) | 9.9 ± 3.1 | 10.4 ± 2.5 | 9.6 ± 2.7 | 7.5 ± 2.5 | 9.2 ± 5.5 | 9.4 ± 3.2 | 0.036 |
| IgA (g/L) | 3.1 ± 1.4 | 2.8 ± 0.8 | 3.4 ± 1.1 | 2.9 ± 1.2 | 2.7 ± 0.9 | 3.1 ± 1.1 | 0.267 |
| C3 (g/L) | 1.01 ± 0.31 | 1.01 ± 0.21 | 0.96 ± 0.20 | 0.95 ± 0.19 | 1.00 ± 0.24 | 0.98 ± 0.22 | 0.837 |
| C4 (g/L) | 0.21 ± 0.06 | 0.27 ± 0.08 | 0.26 ± 0.77 | 0.27 ± 0.53 | 0.27 ± 0.52 | 0.26 ± 0.69 | 0.128 |
| Total crescents (%) | 0% (0–0) | 15.1 (9.5–20.5) | 39.1 (30.0–52.6) | 64.3 (54.8–74.0) | 82.3 (78.7–86.6) | 35.1 (11.8–64.3) | <0.001 |
| Cellular+fibrocellular crescents (%) | 0 (0–0) | 12.1 (8.8–15.9) | 33.3 (30.0–40.0) | 60.0 (52.4–66.7) | 81.5 (78.0–86.5) | 32.5 (10.5–57.4) | <0.001 |
| Fibrous crescents (%) | 0 (0–0) | 0 (0–0) | 0 (0–9.10) | 0 (0–6.8) | 0 (0–0) | 0 (0–0) | 0.283 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum creatinine; IgAN, IgA nephropathy.